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Abstract.
The role of ATP-binding Cassette G1 (ABCG1) transporter in human pathophysiology is still largely unknown. Indeed, beyond its role in mediating free cholesterol efflux to HDL, ABCG1 transporter equally promotes lipid accumulation in a triglyceride (TG)-rich environment through regulation of the bioavailability of Lipoprotein Lipase (LPL).
As both ABCG1 and LPL are expressed in adipose tissue, we hypothesize that ABCG1 is implicated in adipocyte TG storage and could be then a major actor in adipose tissue fat accumulation.
Silencing of Abcg1 expression by RNAi in 3T3-L1 preadipocytes compromised LPL-dependent TG accumulation during initial phase of differentiation. Generation of stable Abcg1 Knockdown 3T3-L1 adipocytes revealed that Abcg1 deficiency reduces TG storage and diminishes lipid droplet size through inhibition of Pparγ expression. Strikingly, local inhibition of adipocyte Abcg1 in adipose tissue from mice fed a high fat diet led to a rapid decrease of adiposity and weight gain. Analysis of two frequent ABCG1 SNPs (rs1893590 (A/C) and rs1378577 (T/G)) in morbidly obese individuals indicated that elevated ABCG1 expression in adipose tissue was associated with an increased PPARγ expression and adiposity concomitant to an increased fat mass and BMI (haplotype AT>GC). The critical role of ABCG1 regarding obesity was further confirmed in independent populations of severe obese and diabetic obese individuals.
For the first time, this study identifies a major role of adipocyte ABCG1 in adiposity and fat mass growth and suggests that adipose ABCG1 might represent a potential therapeutic target in obesity.
Introduction.
The ATP-binding cassette G1 (ABCG1) transporter has been proposed to promote cellular cholesterol efflux to HDL (1) and targeted disruption of Abcg1 was shown to induce massive tissue neutral lipid accumulation in mice fed a high-fat/high-cholesterol diet (2) . However the precise role of ABCG1 is still matter of debate, especially in human pathophysiology (3) .
We recently reported that two frequent ABCG1 SNPs (rs1893590 and rs1378577) were significantly associated to plasma lipoprotein lipase (LPL) activity in the Regression Growth Evaluation Statin Study (REGRESS) population (4) . Analysis of the relationship between ABCG1 genotype and LPL led us to propose a mechanism by which ABCG1 controls macrophage LPL activity through modulation of membrane lipid rafts to promote intracellular lipid accumulation and foam cell formation in a triglyceride (TG)-rich context (4) . Thus, beyond a role in sterol export to HDL, ABCG1 may equally contribute to intracellular fatty acid accumulation and lipid storage in metabolic situations associated with elevated levels of circulating TG-rich lipoproteins. Consistent with a role of Abcg1 in lipid storage, random insertion of modified transposable elements of the P-family in Drosophila melanogaster identified the CG17646 locus, the Drosophila ortholog of Abcg1, as a candidate gene for TG storage (5) . Moreover, total ablation of Abcg1 in mice fed a high fat diet devoid of cholesterol (5) reduced TG accumulation in the adipose and liver tissues. However the cellular mechanisms underlying this phenotype, and more specifically the tissue-specific contribution of Abcg1, were not elucidated.
Considered together, these data prompted us to evaluate the function of ABCG1in adipocytes which are professional cells for TG storage.
ATP-Binding Cassette G1 is expressed in adipocytes and in adipose tissue of mice, which develop diet-induced obesity (5; 6). Moreover, adipose tissue is a major source of LPL (7) which critically controls TG accumulation by generating free fatty acids from circulating lipoproteins (8) .
Our data demonstrate that silencing of Abcg1 expression in adipocyte reduced LPL activity and alters lipid homeostasis. Moreover, Abcg1 deficiency resulted in inhibition of Pparγ expression and alteration of adipocyte maturation. In vivo, local lentiviral-mediated adipose tissue targeting of Abcg1 rapidly reduced adiposity and high-fat diet-induced weight gain in mice. More strikingly, we observed that ABCG1 genotype in humans was associated to fat mass formation and obesity in independent populations of obese individuals, thereby highlighting the critical role of ABCG1 in the Research Design and Methods.
Morbidly obese population.
Middle-aged (42.0 ± 0.04 years) morbidly obese patients (n=1320; BMI = 45.5 ± 0.07 Kg/m 2 ) of Caucasian origin (Sex ratio M/F = 0.33) were recruited at the Department of Nutrition at the Pitié-Salpêtrière hospital, Paris, France (9) . Patients were phenotyped for a series of bioclinical variables.
Body composition in this population was evaluated by biphotonic absorptiometry (DXA) as described (10) . All subjects gave their informed written consent to participate in the genetic study (Clinical Research Contracts), which was approved by the local ethic committee.
The severe obese and diabetic obese populations are described in Supplementary Materials.
In a subset of patients' candidate for bariatric surgery (ABCG1 AT haplotype), subcutaneous adipose tissue pieces were sampled, after an overnight fast, in the s.c. peri-umbilical by needle biopsy under local anesthesia (1% xylocaïne). Biopsies were washed and stored in RNA Later preservative solution (Qiagen) at −80°C until analysis. Total RNA was extracted from adipose tissue biopsies using the RNeasy total RNA minikit (Qiagen). Total RNA concentration and quality was confirmed using the Agilent 2100 bioanalyzer (Agilent Technologies).
Genotyping.
Genotyping of ABCG1 SNPs (rs1893590 and rs1378577) was performed using TaqMan® SNP genotyping assay (Applied Biosystems). Hardy-Weinberg equilibrium was respected for both ABCG1 SNPs in the obese populations studied.
Culture and differentiation of adipocytes.
The 3T3-L1 preadipocytes (Dr J. Pairault, Paris) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum and 2 mM glutamine. Differentiation of confluent preadipocytes was initiated with 0.25 µM insulin, 1.25 µM dexamethasone and 250 µM 3-isobutylmethyl-1-xanthine) in DMEM (4.5 g/L glucose) supplemented with 10% FBS. After 3 days, the culture medium was switched to DMEM (4.5 g/L glucose) supplemented with 10% FBS and 100 nM Insulin for 2 days. Then, 3T3-adipocytes were allowed to differentiate in DMEM (4.5 g/L glucose) containing 10% FBS, replaced every other day for 15 days.
Silencing of Abcg1 expression was performed by application of siRNA oligonucleotides (Dharmacon) targeted to the cDNA sequence of mouse Abcg1 gene (NM_009593). Transfection of 3T3-L1 preadipocytes and differentiated adipocytes with siRNA was achieved using the Nucleofector technology (Lonza) according to the manufacturer's protocol. For each experiment, 2 x 10 6 cells and 100 pmol siRNA were diluted in 100 µl of V solution and processed with A-033 program.
Human preadipocytes (Promocell, Heidelberg, Germany) were cultured and differentiated as recommended by the manufacturer. Differentiation efficiency was validated by quantifying the induction of adipocyte marker mRNA levels (ADIPOQ, LEP and PPARγ).
Generation of stable Abcg1 Knockdown 3T3-L1 adipocytes.
Control shRNAs and validated oligonucleotides encoding shRNAs targeting the cDNA sequence of mouse Abcg1 gene (NM_009593) (R1 sense: 5 '-GAT CCC CGG AAA GGT CTC CAA TCT CGT TCA   AGA GAC GAG ATT GGA GAC CTT TCC TTT TTG GAA A-3' and R1 antisense: 5'-AGC TTT TCC   AAA AAG GAA AGG TCT CCA ATC TCG TCT CTT GAA CGA GAT TGG AGA CCT TTC CGG G-3';   R2 sense: 5'-GAT CCC CGA GAA GAC CTG CAC TGC GAT TCA AGA GAT CGC AGT GCA GGT   CTT CTC TTT TTG GAA A-3' and R2 antisense: 5'-AGC TTT TCC AAA AAG AGA AGA CCT GCA   CTG CGA TCT CTT GAA TCG CAG TGC AGG TCT TCT CGG G-3') were annealed and cloned into pSUPER as previously described (11) . The shRNA expression cassette was then transferred into the XhoI/EcoRI site of the pRVH1-puro retroviral vector and recombinant knockdown viruses were generated using the human Phoenix gag-pol packaging cell line (obtained from the National Gene Vector Biorepository, Indianapolis) as previously described (12) . Preadipocytes 3T3-L1 were plated in 6-well plates (1 x 10 5 cells per plate) in DMEM supplemented with 10% calf serum. After 48 hours, media was aspirated and cells were infected with 1mL of either supernatant from Phoenix cells containing control (R-Ctrl) or Abcg1 KD (R1 and R2) retroviral particles supplemented with 4 µg/mL of hexadimethrine bromide (Polybrene, Sigma) or lentiviral particles expressing control shRNA (L-Ctrl) or shRNAs targeting the cDNA sequence of mouse Abcg1 gene (NM_009593) (L1, L2, L3) (Sigma).
Selection of virus-transduced 3T3-L1 preadipocytes was achieved by incubation with 4 µg/mL puromycin (Invitrogen) for 6 days. Stable Ctrl and Abcg1 KD 3T3-L1 clones were then trypsinized and reseeded into DMEM (4.5 g/L glucose) supplemented with 10% FBS and 4 µg/mL puromycin (Invitrogen) and differentiated into adipocytes as described above.
RNA extraction, reverse-transcription and quantitative-PCR.
Total RNA from cell culture or tissues were extracted using the NucleoSpin RNA II kit (MachereyNagel) or TRIzol reagents (Euromedex), respectively, according to the manufacturer's instructions.
Reverse transcription and real-time qPCR using a LightCycler LC480 (Roche) were performed as previously described (13 Quantification of apoE secretion. Secreted apoE in the culture media of 3T3-L1 adipocytes were quantified by ELISA (Cloud-Clone Corp., Houston, USA) according to the manufacturer's instructions and normalized to cell protein levels.
Lipoprotein lipase activity measurement and cellular lipid quantification.
LPL activity was determined with a 50-µl aliquot of culture medium using a LPL activity assay kit (Roar, New York, USA) according to the manufacturer's instructions. Intracellular total lipase activity was measured using a lipase activity assay kit III (Sigma, Saint-Quentin Fallavier, France). Results were normalized to cell protein levels. When indicated, 3T3-L1 adipocytes were incubated for 16 hours at 37°C with either 250 µM sphingomyelin (from chicken egg yolk, Sigma) or with 3 U/mL sphingomyelinase (from Staphylococcus aureus, Sigma) in order to enrich or deplete membranes in sphingomyelin, respectively, or with 1 mM methyl-β-cyclodextrin (in PBS, Sigma) to remove free cholesterol at the plasma membrane. Quantification of cellular triglyceride, total and free cholesterol mass was performed as previously described (14) . 
Immunofluorescence.
A portion of epididymal adipose tissue was fixed in 10% formalin overnight at 4°C before being embedded in paraffin. Five-micrometre-thick paraffin tissue sections were dewaxed with xylene and graded ethanol, and antigen unmasking was performed by heating the sections in 10 mmol/l citrate buffer, pH 6.0, at 750W for 15 min in a domestic microwave. Then, sections were washed twice in phosphate-buffered saline and saturated with 3% bovine serum before staining with primary antibodies against: ABCG1 (Novus, Littleton, USA), Perilipin (Progen, Heidelberg, Germany 
Western blot analysis.
Cell proteins were extracted using 200µL M-PER reagent (Pierce) containing protease inhibitors and were subsequently separated on a 4-12% Bis-Tris gel (Invitrogen). Proteins (25 µg per lane) were transferred to nitrocellulose and the membrane was blocked with Casein blocker solution for 1h.
Membranes were then incubated overnight at 4°C with a rabbit anti-Abcg1 (NB400-132; Novus), or anti-Pparγ (C26H12) (2435, Cell Signaling), or anti-Fabp4 (2120, Cell Signaling) or with guinea pig anti-perilipin (GP29, Progen) antibody diluted at 1:500 and revealed with either IRDye 800CW-conjugated goat anti-rabbit or donkey anti-guinea pig (Li-Cor) at 1: 10000 for 1 hour. Detection was performed using an Odyssey infrared imaging system (Li-Cor).
Statistical analysis.
Linkage disequilibrium between both SNPs was calculated with Haploview 4.1. Associations between phenotypes and genotypes were tested with multivariate linear regression models. All phenotypes were transformed to log 10 before testing for associations. Genotype-phenotype association tests were performed with R 2.8.2. Association between haplotypes and phenotypes were performed with Hapstat 3.0. All models were adjusted for age and sex; models testing associations with CRP, IL6 and Adiponectin were also adjusted for BMI. Finally, models testing associations with triglycerides, total cholesterol, HDL, Lp(a), ApoA1 and ApoB were also adjusted for BMI and medical treatment for 
RNAi-mediated Abcg1 targeting decreases LPL-dependent cell triglyceride storage in preadipocytes.
Analysis of Abcg1 expression during the course of differentiation of 3T3-L1 preadipocytes into mature adipocytes indicated that Abcg1 mRNA levels were increased by ~40-fold during adipocyte differentiation ( Figure 1A ). In agreement with a role for Abcg1 in TG storage, the accumulation of TG was significantly correlated with Abcg1 mRNA levels ( Figure 1B ; r 2 =0.9, p<0.0001).
We previously reported that macrophage ABCG1 promotes TG storage by modulating LPL activity (4) . In order to test whether the same mechanism is operative in adipocytes, Abcg1 expression was silenced in 3T3-L1 preadipocytes using specific siRNAs which did not alter adipocyte Together, these data indicate that TG accumulation during the initial phase of adipocyte differentiation is LPL-dependent and is compromised by Abcg1 invalidation.
Impaired maturation in stable Abcg1 knockdown 3T3-L1 adipocytes.
To explore the impact of prolonged inhibition of Abcg1 expression on adipocyte maturation, stable Abcg1 KD 3T3-L1 fully differentiated adipocytes were generated using either lentiviral or retroviral particles expressing shRNAs targeted to distinct regions of the Abcg1 mRNA ( Figure 2 ).
Stable knockdown of Abcg1 (Abcg1 SKD), either by lentiviruses (L1 to L3 vs L-Ctrl) or by retroviruses (R1-R2 versus R-Ctrl), led to a marked reduction in Pparγ, Fabp4, C/ebpα, Perilipin, Cd36
and Hsl mRNA expression (Fig. 2B-G) . The expression of some others genes, including Fas or C/ebpβ, wich are also known to participate in adipocyte differentiation, remained unaffected. To note that expression of Abca1 in adipocyte was very recently reported to influence adipocyte lipid homeostasis (19) . This observation may be important since Abcg1 deficiency in mouse macrophages was proposed to be compensated by an increase of Abca1 expression (20) . However such elevation of Abca1 expression was not observed in our conditions when Abcg1 was knocked down in 3T3-L1 adipocytes (Fig. 2J ). The reduction of Pparγ, Perilipin and Fabp4 expression was confirmed at the protein level ( Figure 3A-E) . Strikingly, lipid accumulation was reduced markedly in Abcg1 SKD adipocytes as compared to stable 3T3-L1 control cells (Fig. 3F) and was confirmed by decrease in lipid droplet diameter (-46%, p<0.05; Fig. 3G ) and lower intracellular TG storage (-45%, p<0.005; Fig.   3H ). Moreover, 24h-treatment with exogenous bLPL partially rescued TG storage in Abcg1 SKD adipocytes, while total restoration was observed when bLPL was added throughout the course of adipocyte maturation (from D0 to D10), (Fig. 3I) .
Consistent with the well-established role of Abcg1 in cholesterol transport, Abcg1-deficient adipocytes exhibited reduced capacity to promote free cholesterol efflux to HDL (-31%, p<0.005, Fig.   3J ), even if cell free cholesterol mass was lowered (-60%, p<0.005; Fig 3K) . Such a decrease in intracellular cholesterol levels appeared to be accompanied by increased mRNA amounts of genes involved in cholesterol synthesis in Abcg1 SKD adipocytes (Supplementary Figure 1A-D) .
Accumulation of sphingomyelin in stable Abcg1 knockdown adipocytes reduces LPLdependent TG storage.
ABCG1 was reported to promote export not only of free cholesterol but also phospholipids, such as sphingomyelin (SM) (15) which was described to inhibit LPL activity (21; 22) . Therefore, we next address the hypothesis that an accumulation of SM, found in large amounts in lipid raft domains, was responsible of the reduced LPL activity and the subsequent impaired TG storage in Abcg1 SKD adipocytes. Quantification of SM mass by LC-MS revealed that stable Abcg1 knockdown in 3T3-L1
adipocytes was accompanied by a reduced SM efflux (-14%, p<0.0005; Fig. 4A ) which led to a marked increase of intracellular SM content (+48%, p<0.0005; Fig. 4B ) in those cells in comparison to control adipocytes. More strikingly, depletion of SM by sphingomyelinase in Abcg1 SKD adipocytes restored LPL activity in a comparable level to that observed in control adipocytes (Fig. 4C ) and promoted TG storage (Fig. 4D) . The contribution of SM in this mechanism was further strengthened by the observation that enrichment of control adipocytes with SM led to an impaired TG storage similar to Abcg1 SKD adipocytes (Fig. 4D) . A treatment with 1 mM methyl-β-cyclodextrin for 16 hours which removes cholesterol but not SM from plasma membrane (23; 24) was without effect on intracellular TG levels in Abcg1 SKD adipocytes (Supplementary Figure 1E) , suggesting that free cholesterol in lipid rafts was not responsible for the reduced TG storage in those cells. Finally, because Abcg1 deficiency may be associated to an increased apoE secretion (25) , which may affect LPL activity (26), apoE secretion from control and Abcg1 SKD adipocytes was examined. As shown in Supplementary Figure   1F , no difference in apoE secretion was detected in Abcg1 SKD adipocytes in comparison to control cells.
Taken together, those results support the mechanism through which Abcg1 deficiency led to a reduced sphingomyelin efflux and a concomitant increased SM content at the plasma membrane, likely associated to lipid rafts, which decreases LPL activity and subsequent TG storage.
In vivo silencing of Abcg1 expression locally in adipose tissue attenuates fat storage upon high-fat diet.
In order to further investigate the in vivo role of adipocyte Abcg1, adipose tissue Abcg1 was silenced by local delivery of lentiviral particles encoding either control shRNAs (L-Ctrl) or Abcg1 shRNAs (L-Abcg1) in epididymal adipose tissue. Injected C57BL/6 mice were maintained on a high-fat diet according to the experimental design presented on Figure 5A . Expression of Abcg1 in adipocytes in adipose tissue from mice fed a high fat diet (W4) was visualized by immunofluorescence ( Figure   5B ). Injection of lentiviral particles expressing GFP alone into epididymal adipose tissue confirmed that this strategy was efficient in targeting adipocytes from adipose tissue (W4, Figure 5C (Fig. 5G) . No effect was observed in endothelial cells isolated from adipose tissue (Fig. 5G) or in others organs such as intestine (Fig. 5H) or liver (Fig. 5I ).
All mice were maintained on a high-fat diet for four weeks following injection and weight gain was evaluated in the two groups (W4). L-Abcg1-injected mice gained less weight than L-Ctrl injected mice (-24%, p<0.05, respectively, Fig. 6A ) and had a decreased epididymal fat mass (-26%, p<0.05, Fig. 6B ), suggesting lower adipose tissue fat storage. Indeed, mean adipocyte diameter was significantly smaller than that in epididymal adipose tissue from L-Ctrl mice (Fig. 6C) . In agreement, mRNA levels of leptin were decreased in adipose tissue from L-Abcg1 mice as compared to L-Ctrl mice (Fig. 6D) . Analysis of food intake ( Fig. 6E ) and locomotor activity (Fig. 6F-G) indicated that reduced weight gain in locally injected mice did not result from overt alteration of energy balance.
Additional analysis of metabolic parameters in L-Abcg1 and L-Ctrl mice is presented in Supplementary   Table 1 . The genes whose expression was downregulated in stable Abcg1 SKD mouse adipocytes generated in culture were also strikingly affected in Abcg1-silenced fat pads, namely Pparγ, Perilipin, Fabp4, Cd36, Hsl and C/ebpα (Fig. 6H-M) whereas that of C/ebpβ or Fas was not altered (Fig. 6N-O) .
Expression of inflammatory and insulin-resistance genes in epididymal adipose tissue from L-Ctrl and L-Abcg1 mice is shown in Supplementary Figure 2 .
Taken together, these results support a critical role of Abcg1 in adipocyte lipid storage and indicate that local inhibition of Abcg1 in adipose tissue of mice impaired fat storage under a high-fat diet.
A higher expression of ABCG1 in human adipose tissue is associated with increased fat mass and corpulence.
Page 16 of 46 Diabetes
We presently demonstrate that adipocyte Abcg1 contributes to TG storage and adiposity and hypothesize that an elevated expression of ABCG1 might be associated with an increased fat mass in obese subjects. To evaluate this question, we took the opportunity to examine functional ABCG1 in the REGRESS cohort (4). As previously described (4), in vitro analysis of ABCG1 promoter activity according to ABCG1 haplotypes confirmed that the frequent AT haplotype was associated with a higher transcriptional activity than the rare CG haplotype ( Figure 7A ). Analysis of ABCG1 expression in biopsies of adipose tissues isolated from a subset of obese patients displaying either the AT or CG haplotypes revealed that mRNA levels of ABCG1 were 27% (p<0.05) more elevated in adipose tissues from patients carrying the AT haplotype relative to those carrying the CG haplotype (Fig. 7B) . It is to note that ABCG1 expression in primary human preadipocytes was significantly induced upon differentiation into adipocytes (Supplementary Figure 3A) .
In agreement with our data in Abcg1-deficient adipocytes, levels of mRNAs coding for genes involved in adipocyte differentiation (PPARγ , CD36, PLIN1) were increased in adipose tissue from obese patients carrying the AT haplotype as compared to those carrying the CG haplotype ( ABCG1 expression in adipose tissue from obese patients was positively correlated to the adipocyte diameter (r=0.51, p=0.023, Fig. 7G ). Importantly, obese individuals carrying the AT functional haplotype displayed a significantly higher DXA-evaluated fat mass together with a lower fatfree mass ( Fig. 7H and 7I ) (p<0.05) than those carrying the CG haplotype.
Moreover, the two ABCG1 SNPs were significantly associated with BMI; individuals carrying the -204AA or the-134TT genotype displaying the highest BMI (p=0.0034 and p=0.011, respectively) ( Figure 7J ). Haplotype analysis confirmed that the AT haplotype (-204A / -134T) was significantly associated with BMI (p=0.006); moreover, BMI increased in parallel with increase in the amount of the AT haplotype ( Figure 7K ). Association of both ABCG1 SNPs with BMI was still observed after adjustment with diabetes or HOMA index (Supplementary Table 2 ). To note that ABCG1 SNPs rs1378577 and rs1893590 were not associated with HOMA index after adjustment or not with BMI (data not shown). In addition, obese individuals carrying the -134TT genotype (rs1378577, most frequent genotype) also displayed the highest fat mass index (p=0.0242; Fig. 7L ); this effect was equally observed in subjects carrying the -204AA genotype (rs1893590, most frequent genotype) (p=0.0331). Of note, Adiponectin and CRP levels were significantly associated with both ABCG1
SNPs in this population (Supplementary Figure 3) . However no significant effect of ABCG1 SNPs on plasma lipid and apolipoprotein levels was observed (Supplementary Table 3 Fig. 4D-E) .
Discussion.
In the present study, we unraveled an unexpected role for Abcg1 in the control of lipid homeostasis in adipocytes. Indeed, through a mechanism involving modulation of both LPL activity and regulation of Pparγ, Abcg1 appears to be a critical component in TG storage and adiposity. The central role of Abcg1 in adipocyte is further strengthened following the targeted silencing of its expression locally in adipose tissue in mice fed a high fat diet which led to a rapid reduction in adiposity and weight gain. Consistent with these findings, ABCG1 is associated with adiposity, fat mass and obesity in obese individuals.
These results may initially appear conflicting with respect to the widely described role of Abcg1 in cellular free cholesterol efflux, where its inhibition leads to increase rather than decrease in intracellular lipid accumulation (2) . Indeed, in this way, Abcg1 can protect the cell from the accumulation of free cholesterol which is toxic for cell survival. In agreement with such a role for Abcg1, we presently demonstrated that silencing of Abcg1 expression in differentiated 3T3-L1
adipocyte was accompanied by a significant reduction in free cholesterol efflux to HDL, thereby indicating that this mechanism is also operative in fat cells. However, in contrast to plasma membrane free cholesterol, the large content of free cholesterol associated with lipid droplets, and which is closely proportional to TG storage in adipocytes and fat cell size, is not mobilized for efflux (29) .
Mobilization of free cholesterol in lipid droplets therefore provides an alternative pathway for protection of adipocytes from toxicity. The present study supports the notion that although the role of Abcg1 in cellular free cholesterol efflux mechanisms is crucial in maintaining tissue lipid homeostasis in a cholesterol-rich environment (2), Abcg1 contributes to cellular lipid, mostly triglycerides, accumulation and storage in high fat-rich metabolic states (4; 5). Thus, Abcg1 deficiency (30) (31) (32) as well as expression of human ABCG1 in mice (2; 33) fed an atherogenic diet enriched in cholesterol highlight the role of Abcg1 in protecting tissues, especially the lung, from lipid accumulation without any apparent changes in adipose tissue mass or adiposity. By contrast and coherent with the mechanism described in the present study, Abcg1 KO mice fed a high fat diet devoid of cholesterol did not accumulate lipids in tissues but rather exhibited a reduced adipose tissue formation and were protected against diet-induced obesity (5).
Our data supports a mechanism by which Abcg1 promotes TG storage through the requirement of bioactive LPL (4), as addition of exogenous LPL totally rescued the impaired TG storage observed in Abcg1-deficient adipocytes. Our data led us to propose a mechanism by which Abcg1-mediated export of SM contributes to sustain LPL activity and TG storage in adipocytes.
Indeed, LPL hydrolyzes triacylglycerol-rich lipoproteins allowing the subsequent release and uptake of fatty acids for intracellular TG synthesis. LPL is expressed at very early stages of adipocyte differentiation when cell-cell contact occurs (34) and adipocyte-derived LPL was reported to be a key determinant for efficient TG storage and adipocyte hypertrophy (8) . In agreement with this mechanism, silencing of Abcg1 expression in 3T3-L1 adipocytes was accompanied by marked reduction in TG storages; an effect observed at early stages of adipocyte differentiation. Beyond its role in TG hydrolysis, LPL was also reported to facilitate lipoprotein uptake and thereby to contribute to cellular cholesterol accumulation through this mechanism (14; 35) . Consistent with such a role for LPL, intracellular concentrations of free cholesterol were markedly reduced in Abcg1 KD adipocytes; a finding in agreement with the reduced lipid droplet size observed in Abcg1 SKD adipocytes. The role of ABCG1 in adiposity and obesity through its action on adipocyte LPL activity is supported by studies in human subjects indicating that adipose tissue LPL activity is elevated in obesity (36) . Furthermore, several variants in the LPL gene have been associated with obesity (37; 38) and ob/ob mice with a specific Lpl deficiency in adipose tissue displayed reduced weight and fat mass as compared to control mice (39) .
Alteration of Pparγ and Pparγ-target gene expression likely results from the lower abundance of intracellular cholesterol and fatty acid derivatives delivered by LPL hydrolysis upon silencing of Abcg1 expression in adipocytes. Indeed, fatty acid derivatives are ligands for Pparγ activation and Pparγ expression in adipocytes was reported to be induced by its own activators and /or ligands, such as fatty acids (40) (41) (42) , and cholesterol derivatives through LXR activation (43) . In agreement with this mechanism, some fatty acid derivatives, whose delivery into cells is mediated by LPL, are activators of Pparγ (41) . Interestingly, overexpression of a dominant negative mutant of Pparγ that lacks the 16 COOH-terminal amino acids in 3T3-L1 adipocytes led to a reduction in the rate of free fatty acid uptake, TG storage and adipocyte size, and more interestingly to a decrease in the expression of the perilipin, Fabp4, Cd36, Hsl and C/ebpα genes (44); a similar phenotype to that observed in the present study when Abcg1 expression is silenced in those cells. However, the modest reduction of adipocyte diameter observed in Abcg1 knockdown epididymal adipose tissue in comparison to the more pronounced decrease of the tissue weight leads us to suggest that the decreased Pparγ expression could also alter adipocyte differentiation and adipocyte cell number in vivo.
The participation of Pparγ in the overall mechanism by which Abcg1 contributes to adiposity and obesity is supported by the observation that the adipose-specific Pparγ knockout mice displayed a diminished weight gain and were protected against high fat diet-induced obesity (45) . Taken together, our findings indicate that modulation of LPL activity by Abcg1 in adipocyte might act as an intracellular signaling pathway that controls adipocyte growth through activation of Pparγ and contributes by this mechanism to fat mass formation and development of obesity in humans. Moreover, we presently reported that a higher expression of ABCG1 in adipose tissue from obese individuals carrying the AT haplotype was associated with increased PPARγ, adiposity, fat mass and BMI. However, although targeted deletion of Pparγ in adipose tissue in mice led to an impaired adipose tissue growth, it must be kept in mind that those mice also exhibited deleterious metabolic consequences such as lipid accumulation in liver and in muscle and potentially insulin resistance (45; 46) . The best model fitting the data is shown (dominant). All models were adjusted for age and sex. Data are shown as mean ± SEM. *p<0.05. ). The best model fitting the data is shown (dominant in F and recessive in E). All models were adjusted for age and sex. *p<0.05.
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